AAVX.F Stock Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ABIVAX Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €15.15 |
| 52 Week High | €20.00 |
| 52 Week Low | €10.19 |
| Beta | 1.46 |
| 1 Month Change | 38.36% |
| 3 Month Change | 38.36% |
| 1 Year Change | -5.31% |
| 3 Year Change | -38.89% |
| 5 Year Change | 40.28% |
| Change since IPO | 71.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAVX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 38.4% | 1.5% | 1.2% |
| 1Y | -5.3% | 1.1% | 24.7% |
Return vs Industry: AAVX.F underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: AAVX.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| AAVX.F volatility | |
|---|---|
| AAVX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AAVX.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AAVX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 61 | Marc M. de Garidel | www.abivax.com |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme Fundamentals Summary
| AAVX.F fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$158.01m |
| Revenue (TTM) | US$4.81m |
201.7x
P/S Ratio-6.1x
P/E RatioIs AAVX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAVX.F income statement (TTM) | |
|---|---|
| Revenue | €4.49m |
| Cost of Revenue | €0 |
| Gross Profit | €4.49m |
| Other Expenses | €152.23m |
| Earnings | -€147.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 09, 2024
| Earnings per share (EPS) | -2.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,288.23% |
| Debt/Equity Ratio | 37.7% |
How did AAVX.F perform over the long term?
See historical performance and comparison